Fierce Biotech July 1, 2022
Welcome to this week’s Chutes & Ladders, our roundup of hirings, firings and retirings throughout the industry. Please send the good word—or the bad—from your shop to Max Bayer, and we will feature it here at the end of each week.
FDA adds experienced duo to executive team to advise science, policy
Food and Drug Administration
FIERCE EXECUTIVE SUMMARY
Highly Potent API Drug Product Development and Manufacturing using Micronization Technology
Pharmaceutical drug developers continue to realize the strong therapeutic potential of highly potent active pharmaceutical ingredients (HPAPIs). This is particularly true for therapeutic areas such as oncology, where highly potent drugs are becoming more commonplace. Download this Executive Summary to learn more about Catalent’s approach...
Today's Sponsors
Today's Sponsor